ABOUT AMPHISTA

Amphista Therapeutics is a fast-growing Cambridge-based biotech and the leading European Targeted Protein Degradation (TPD) company. Our unique scientific approach to TPD, one of the hottest areas in modern drug discovery, gives us a range of advantages over other therapeutic strategies.
In addition to an oversubscribed $53M funding round in 2021. We were delighted to recently announce two separate collaboration deals with Bristol Myers Squibb and Merck Healthcare which will allow us to grow and advance our therapeutic portfolio even faster.
Initially founded from the laboratory of Professor Alessio Ciulli (University of Dundee) our team comprises both academic and drug discovery pioneers of the TPD field and a growing R&D team focused on advancing a portfolio of medicines to the clinic using our proprietary next generation TPD technologies.
When you join Amphista, you become a part of a world-class team dedicated to achieving excellence. Our people are pioneers, collaborators and goal driven innovators who thrive in ambiguous environments. The diverse backgrounds across our organisation bring solutions to sciences most complex challenges.
This cultural DNA runs throughout our organisation and we approach each day with energy, optimism and an aligned goal.

Please refer the Job description for details